Related references
Note: Only part of the references are listed.Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression
German Reyes-Botero et al.
NEURO-ONCOLOGY (2014)
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma
J. A. Carrillo et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2012)
IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas
Ichiyo Shibahara et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2012)
Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin
Albert Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours
J. W. Kim et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2011)
Non-Stem Cell Origin for Oligodendroglioma
Anders I. Persson et al.
CANCER CELL (2010)
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Mutant Metabolic Enzymes Are at the Origin of Gliomas
Hai Yan et al.
CANCER RESEARCH (2009)
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients
Yukihiko Sonoda et al.
CANCER SCIENCE (2009)
Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features
Michael D. Jenkinson et al.
BRAIN (2006)
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
